HPV-063 was a follow-up study to HPV-032. SAE data not included in the Cochrane HPV review meta-analysis

HPV-023 was a follow-up study to HPV-001 SAE data not included in the Cochrane HPV review meta-analysis

Follow-up Study to Evaluate the Long-term Efficacy of a HPV Vaccine (580299) in Healthy Young Adult Women in Brazil

SAE data not included in the Cochrane HPV review meta-analysis

744 participants reported enrolled in trials.gov

SAE data not included in the Cochrane HPV review meta-analysis

814 participants reported enrolled in trials.gov

HPV-073 was identified and added to the Cochrane review in the Cochrane editors’ reassessment (1).

V501-028 was identified and added to the Cochrane review in the Cochrane editors’ reassessment (1)

identified as eligible but not included in the Cochrane HPV review.

V503-006 was identified and added to the Cochrane review in the Cochrane editors’ reassessment (1

Listed in the Cochrane review as "not published"; however, HPV-003's clinical study report can be downloaded from GSK trial register. The Cochrane review include data from GSK trial register,

HPV-040 was excluded from the Cochrane review, as it was considered a “phase IV” study (Cochrane review only included phase II and III studies). We included HPV-040 in our list, as a “phase III/IV” study in the freely available CSR from GSKs trial register. HPV-040 includes the bulk of the additional eligible participants: 32,176 of which 20,515 were females.

gender-specific data are available and can be obtained from EMA.

V501-030 had been excluded from the Cochrane review, as gender-specific data could not be obtained. However, the gender-specific data are available and can be obtained from EMA.

V501-046 was identified and added to the Cochrane review in the Cochrane editors’ reassessment (1).

HPV-PRO-002 was identified and added to the Cochrane review in the Cochrane editors’ reassessment (1)

2010-1090/GaReCo is not included in Cochrane review, but data for safety outcomes are eligible for
inclusion: http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012-004007-13-DE

MENACWY-TT-054 is a five-arm trial in which,
during a one-month window, exposure to Cervarix was directly compared to another vaccine (Nimenrix), but
at study completion all arms may have received Cervarix.

Numbers unsure - write to manufacturer

Numbers unsure - write to manufacturer

may be a study that compares females with males that all were vaccinated with Gardasil.
Therefore, V503-018 is “possibly eligible.”

Numbers unsure - write to manufacturer

V505-001 appears to have six arms where
one arm receives “placebo.”

Of 21 studies ideintified (twenty by Jorgensen et al, one by the Cochrane editors () in the list 17 are likely to be included (5 of these idenitifed by the Cochrane Editors), for 5 it is unclear, Four studies in the Jorgensen et al table are inluded in the Cochrane HPV review but available serious adverse event data from the ideintified long term follow up studies has not been used. One study (MENACWY-TT054-NCT01755689) is unlikely to be included but this requires checking. Therefore data from twenty trials will potentially be eligible for inlcusion in the Cochrane HPV review.